This fellowship is the first to actively recruit and support pathologist fellows to train under veterinary pathologists and computer scientists that are currently developing and using deep learning and artificial intelligence to investigate animal models of human infectious disease.
Dr. Breuer’s translational research focus is on the advancement of Tissue Engineered Vascular Grafts (TEVG). TEVG’s are constructed by seeding bone marrow derived mononuclear cells onto a biodegradable tubular scaffold, and then autologously implanting them. The seeded scaffold provides an environment conducive for building new tissue.
Dr. Tamura’s current primary research focus is the development of cancer-targeted immune checkpoint blockade therapy that is at least as effective as currently available antibody-based immune checkpoint blockade therapy while possessing fewer systemic off- target effects than currently available methods.
The use of canine induced pluripotent stem cell models for understanding the pathophysiology of inherited disorders and developing therapeutic approaches. We are particularly focused on inherited cardiomyopathies and neurodegenerative disorders.
Our research team has two main research efforts: 1) Using biomechanical objective outcome measurements (kinematic and kinetic) to evaluate the effects of OA on not only the affected joint but the entire body in dogs; 2) Exploring the interactions of cytokines associated or generated by adipose tissue in the development of osteoarthritis. Our primary research model is naturally occurring canine osteoarthritis (OA).
The proposed fellowship program would consist of two research objectives: 1) preclinical translational models of cardiovascular disease, consisting of evaluation of open-heart and transcatheter valvular therapies/devices , and basic science biomaterials research for improved valvular and vascular graft performance.
Our goal is to establish naturally occurring central nervous system (CNS) aging in dogs as a model of human CNS aging, with long term goals of improving understanding of pathophysiological mechanisms, identification of novel therapeutic targets, and timely and clinically relevant screening of therapies applicable to both dogs and humans.
The Kaeser lab has recently successfully completed a proof-of-principle Chlamydia suis vaccine study in outbred pigs. These studies were enabled by a state-to-the art technique in swine immunology: nine-color flow cytometry. Future studies will use the pig model to test and develop Chlamydia trachomatis vaccines, and they will focus on studying the memory immune cells draining into the genital tract in great detail.
Dissecting the genomic landscape of specific canine tumors (osteosarcoma, hemangiosarcoma, lymphoma) and using those data to interrogate relevant molecular pathways for potential therapeutic intervention.
North Carolina State University, School of Veterinary Medicine
The Comparative Gastroenterology (CGI) Lab led by Drs. Anthony Blikslager and Amanda Ziegler studies translational development of gut health using large animal models, primarily pigs. The research team is fully USDA- and NIH-funded for the next five years to study intensively the roles of nutritional inputs in the development of a healthy and disease-resistant intestinal microbiome, enteric nervous system (ENS), and epithelial barrier.
The Dog Aging Project (DAP), supported by a U19 grant from the National Institute on Aging, is an open science, large-scale longitudinal study of the genetic and environmental determinants of healthy aging in companion dogs, and will include a subset of dogs enrolled in a clinical trial of rapamycin, as a potential healthspan promoting intervention.
FLASH is a high impact, rapidly growing area of research in radiation oncology that stands to revolutionize the clinical delivery of radiotherapy. FLASH utilizes ultrafast dose rates >40 Gray/sec to deliver standard doses of radiotherapy in a fraction of the typical treatment time.
Annie Wayne, Claire Fellman, Shira Doron and Kira Beaulac have an active collaboration in the area of infection control and antimicrobial stewardship and have several funded research projects that are on-going.
We have engineered and characterized a panel of recombinant effectors that function as cell-penetrating, self- delivering NF-κB pathway inhibitors and have demonstrated their efficacy in several models of inflammatory disease.
Our research program focuses on the role of nutrition in the development, progression, and treatment of cardiac diseases, including degenerative mitral valve disease, hypertrophic cardiomyopathy, and dilated cardiomyopathy.
The McLellan lab is focused on solving ocular problems that affect animals and humans, with a particular emphasis on leading causes of irreversible blindness, glaucoma and retinal degeneration. Animal models play a critical role in the development and assessment of safety and efficacy of new treatment strategies for human ocular diseases.
The Ortved Laboratory is focused on understanding the pathophysiology of post-traumatic osteoarthritis (PTOA) and developing gene and cell-based therapies to help regenerate cartilage and prevent the development of PTOA following joint injury.
Fellowship provides a balanced exposure to both experimental models of spinal cord injury and to veterinary clinical research in spinal cord injury (SCI) designed to contribute to translational progress.
This project will evaluate the epithelial and immune cell compartments of intestinal mucosal biopsies in human and canine patients with inflammatory bowel disease, with the goal to identify novel genes or cell subtypes that are similarly altered in canine and human IBD.